GOG-0262 A PHASE III TRIAL OF EVERY-3-WEEKS PACLITAXEL VERSUS DOSE DENSE WEEKLY PACLITAXEL IN COMBINATION WITH CARBOPLATIN WITH OR WITHOUT CONCURRENT AND CONSOLIDATION BEVACIZUMAB (NSC #704865, IND #7921) IN THE TREATMENT OF PRIMARY STAGE II, III OR IV EPITHELIAL OVARIAN, PERITONEAL OR FALLOPIAN TUBE CANCER and ACRIN 6695: PERFUSION CT IMAGING TO EVALUATE TREATMENT RESPONSE IN PATIENTS PARTICIPATING IN GOG-0262

Objective

This is a clinical trial of Carboplatin that will be administered by IV which is standard of care, and Paclitaxel that will be administered by IV which is standard of care, and Bevacizumab that will be administered by IV which is investigational.

IRB Protocol Number

10-1222

Principal Investigator(s)

SUSAN DAVIDSON

Cancer Trials

• Female Reproductive Cancer

Sponsor(s)

GOG

Contact

SIDNEY MCINTOSH at 720-848-0681
or SIDNEY.MCINTOSH@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period that can be ongoing as long as there is evidence that your tumor is not growing and you are not experiencing any unacceptable side effects. A follow up period will consist of phone contact, physician contact, and clinic visits. // Eligibility criteria include but are not limited to 18 years or older with ovarian, fallopian tube or primary peritoneal cancer.